Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland DOI Open Access
Izabela Jęśkowiak,

Paulina Nowotarska,

Patrycja Grosman-Dziewiszek

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(20), С. 6173 - 6173

Опубликована: Окт. 17, 2024

The COVID-19 pandemic necessitated rapid and widespread vaccination efforts, which proved critical in reducing the severity mortality of virus. However, interplay between vaccinations, pre-existing skin conditions, other comorbidities still needs to be explored. This study investigated occurrence adverse events following immunization (AEFIs) with vaccines individuals chronic diseases within a Central European cohort.

Язык: Английский

Did We Overreact? Insights on COVID-19 Disease and Vaccination in a Large Cohort of Immune-Mediated Inflammatory Disease Patients during Sequential Phases of the Pandemic (The BELCOMID Study) DOI Creative Commons
J Geldof, Marie Truyens, João Sabino

и другие.

Vaccines, Год журнала: 2024, Номер 12(10), С. 1157 - 1157

Опубликована: Окт. 11, 2024

Introduction: As the COVID-19 pandemic becomes an endemic state, still many questions remain regarding risks and impact of SARS-CoV-2 infection vaccination in patients with immune-mediated inflammatory diseases (IMIDs) who were excluded from phase 3 trials. Methods: The BELCOMID study collected patient data serological samples a large, multicentric IMID cohort that was prospectively followed during sequential stages pandemic. Patients stratified according to status into five groups across three sampling periods. Interactions between infection, status, IMID-treatment modalities course explored. Results: In total, 2165 IBD, dermatological or rheumatological participated. rates increased over highest had refused every vaccine. After baseline vaccination, serologic spike (S)-antibody responses attenuated by particular types immune-modulating treatment: anti-TNF, rituximab, JAKi, systemic steroids, combined biologic/immunomodulator treatment. Nonetheless, S-antibody concentration progressively received booster reaching 100% seroconversion rate two vaccines. Previous found as predictor higher response. vaccine showed lowest S-seroconversion (53.8%). Multiple logistic regression did not identify previous risk factor for flare-up. Furthermore, no flare-up vaccination. Conclusions: Altogether, provides evidence efficacy safety confirms importance repeated patients.

Язык: Английский

Процитировано

0

Impact of Comorbidities and Skin Diseases on Post-Vaccination Reactions: A Study on COVID-19 Vaccinations in Poland DOI Open Access
Izabela Jęśkowiak,

Paulina Nowotarska,

Patrycja Grosman-Dziewiszek

и другие.

Journal of Clinical Medicine, Год журнала: 2024, Номер 13(20), С. 6173 - 6173

Опубликована: Окт. 17, 2024

The COVID-19 pandemic necessitated rapid and widespread vaccination efforts, which proved critical in reducing the severity mortality of virus. However, interplay between vaccinations, pre-existing skin conditions, other comorbidities still needs to be explored. This study investigated occurrence adverse events following immunization (AEFIs) with vaccines individuals chronic diseases within a Central European cohort.

Язык: Английский

Процитировано

0